医学
罗米普洛斯蒂姆
血小板生成素
埃尔特罗姆博帕格
临床试验
血小板生成素受体
化疗
肿瘤科
内科学
重症监护医学
免疫学
血小板
免疫性血小板减少症
干细胞
遗传学
造血
生物
作者
Andrew B. Song,Hanny Al‐Samkari
标识
DOI:10.1080/17474086.2023.2201428
摘要
Introduction Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer treatment, frequently leading to reduced relative dose intensity, and is associated with reduced survival. Given the lack of FDA-approved therapies for CIT, thrombopoietin receptor agonists (TPO-RAs) have received significant attention for treatment and prevention of CIT.Areas covered This review will summarize the development of prior agents for treatment of CIT, discuss the existing literature investigating the use of TPO-RAs in CIT primarily in patients with solid tumor malignancies, and offer insights on the future direction of TPO-RAs and other therapeutics for CIT.Expert opinion In alignment with NCCN guidelines, we recommend that patients with CIT participate in a clinical trial for consideration of TPO-RA treatment or consider off-label use of romiplostim when participation in clinical trials is not possible. The literature to date supports the use of TPO-RAs for treatment of persistent CIT. Further data is needed to describe the long-term efficacy, safety, and prescribing practices of TPO-RAs in a diverse patient population with a variety of tumor types and chemotherapy regimens in addition to exploring the underlying biology of CIT.
科研通智能强力驱动
Strongly Powered by AbleSci AI